Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children

被引:20
作者
Lapphra, Keswadee [1 ]
Vanprapar, Nirun [1 ]
Chearskul, Sanay [1 ]
Phongsamart, Wanatpreeya [1 ]
Chearskul, Pimpanada [1 ]
Prasitsuebsai, Wasana [1 ]
Chokephaibulkit, Kulkanya [1 ]
机构
[1] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Pediat, Bangkok 10700, Thailand
关键词
Efficacy; Tolerability; Nevirapine; Efavirenz; HIV; Children;
D O I
10.1016/j.ijid.2007.10.008
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based highly active antiretroviral therapy (HAART) has been the most affordable regimen for the HIV-infected in developing countries. There are limited data comparing nevirapine (NVP) to efavirenz (EFV) in HIV-infected children. This study aimed to assess the efficacy and tolerability of NVP-based regimens compared to EFV-based regimens in HIV-infected children in Thailand. Methods: The medical records of HIV- infected children who had received NNRTI-based regimens for more than 6 months at the Department of Pediatrics, Siriraj Hospital, Mahidol University, Thailand, were reviewed. Results: Of the 139 HIV- infected children studied, 70 were male, and the median age at treatment initiation was 6.08 years (range 0.32-14.56 years); the median duration of follow-up was 36 months (range 6-66 months). The median baseline CD4 cell count was 185 cells/mm(3) (range 2-3482 cells/mm3) and the median baseline CD4 percentage was 7.20% (range 0.11-36.57%). An NVP-based regimen was initiated in 61 (44%): 38 antiretroviral (ARV)-naive and 23 ARV-experienced. An EFV-based regimen was initiated in 78 (56%): 34 ARV-naive and 44 ARV-experienced. The CD4 cell count and percentage gains were not different between the NVP and EFV groups in both the ARV-naive and the ARV-experienced. However, ARV-naive children who received an EFV regimen had significantly lower baseline CD4 levels than those who received an NVP regimen. ARV-naive children had a better CD4 response than the ARV-experienced. The survival rates of children in the NVP groups were not different from those in the EFV groups for both the ARV-naive and the ARV-experienced. Treatment failure occurred in one ARV-naive NVP case (2.6%), two ARV-naive EFV cases (5.8%), and nine ARV-experienced NVP cases (39%) at 24 months of treatment, and 11 ARV-experienced EFV cases (25%) at 18 months of treatment. Seven (10%) children had adverse effects from treatment with NVP. The main side effects were rash and hepatitis; six had to switch to EFV. Four (5%) children had adverse effects from treatment with EFV; two had to switch to NVP. Conclusions: Both NVP- and EFV-based HAART regimens were effective in children in Thailand for at least 3 years. HIV-infected Thai children generally tolerated NNRTI well. (C) 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:E33 / E38
页数:6
相关论文
共 25 条
[1]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[2]  
[Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1
[3]   Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.NA) study [J].
Cozzi-Lepri, A ;
Phillips, AN ;
Monforte, AD ;
Piersantelli, N ;
Orani, A ;
Petrosillo, N ;
Leoncini, F ;
Scerbo, A ;
Tundo, P ;
Abrescia, N ;
Moroni, M .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (08) :1062-1069
[4]   Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients [J].
Fatkenheuer, G ;
Theisen, A ;
Rockstroh, J ;
Grabow, T ;
Wicke, C ;
Becker, K ;
Wieland, U ;
Pfister, H ;
Reiser, M ;
Hegener, P ;
Franzen, C ;
Schwenk, A ;
Salzberger, B .
AIDS, 1997, 11 (14) :F113-F116
[5]  
Keiser Philip, 2002, HIV Clin Trials, V3, P296
[6]   Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen [J].
Le Moing, V ;
Chêne, G ;
Carrieri, MP ;
Alioum, A ;
Brun-Vézinet, F ;
Piroth, L ;
Cassuto, JP ;
Moatti, JP ;
Raffi, F ;
Leport, C .
AIDS, 2002, 16 (01) :21-29
[7]   Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E [J].
Lolekha, R ;
Sirivichayakul, S ;
Siangphoe, U ;
Pancharoen, C ;
Kaewchana, S ;
Apateerapong, W ;
Mahanontharit, A ;
Chotpitayasunondh, T ;
Ruxrungtham, K ;
Phanuphak, P ;
Ananworanich, J .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (02) :309-312
[8]   Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection [J].
Manosuthi, W ;
Sungkanuparph, S ;
Vibhagool, A ;
Rattanasiri, S ;
Thakkinstian, A .
HIV MEDICINE, 2004, 5 (02) :105-109
[9]   Virological suppression at 6 months is related to choice of initial regimen in anti retroviral-naive patients: a cohort study [J].
Matthews, GV ;
Sabin, CA ;
Mandalia, S ;
Lampe, F ;
Phillips, AN ;
Nelson, MR ;
Bower, M ;
Johnson, MA ;
Gazzard, BG .
AIDS, 2002, 16 (01) :53-61
[10]   Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor [J].
Mocroft, A ;
Gill, MJ ;
Davidson, W ;
Phillips, AN .
AIDS, 1998, 12 (16) :2161-2167